Prospective, placebo-controlled trial of 5 vs 10 days of oral prednisolone in acute adult asthma

被引:29
作者
Jones, AM
Munavvar, M
Vail, A
Aldridge, RE
Hopkinson, L
Rayner, C
O'Driscoll, BR
机构
[1] Hope Hosp, Dept Cardio Resp Med, Salford M6 8HD, Lancs, England
[2] Univ Manchester, Hope Hosp, Biostat Grp, Salford M6 8HD, Lancs, England
关键词
asthma; corticosteroids; prednisolone; treatment;
D O I
10.1053/rmed.2002.1369
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The optimal duration of oral steroid treatment in the management of acute adult asthma is unclear. We prospectively studied the effect of 5 vs. 10 days of oral prednisolone in patients with acute asthma requiring hospital admission. Methods: Each patient received 40 mg of enteric-coated prednisolone daily for 5 days, followed by 5 days of 40 mg prednisolone daily (n=24) or placebo (n=20). All were given their usual inhaled asthma therapy including inhaled corticosteroids. Patients kept PEF and symptom diaries for 21 days. Results: For the 5-day treatment group mean (95% CI) early morning PEF was 6 (-47,+36) 1/min lower today 21 (P=0.78). There was no evidence of differences in other PEF measures (morning post-bronchodilator, evening or worst of day). One patient in each group had an exacerbation requiring further oral steroids during the 21-day observation period. Asthma symptom scores were worse in the 5-day group on days 6-21 but the significance of this finding was uncertain, as a difference had emerged by day 5 (prior to trial entry). Conclusions: It may be possible to reduce the standard steroid course to 5 days in acute adult asthma, provided all patients receive inhaled steroids and a personal asthma management plan. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:950 / 954
页数:5
相关论文
共 50 条
  • [41] Efficacy of Lactobacillus Administration in School-Age Children with Asthma: A Randomized, Placebo-Controlled Trial
    Huang, Chian-Feng
    Chie, Wei-Chu
    Wang, I-Jen
    NUTRIENTS, 2018, 10 (11)
  • [42] A randomized placebo-controlled trial of traditional Chinese medicine as an add-on therapy to oral montelukast in the treatment of mild persistent asthma in children
    Chan, Pak-hong
    To, Ching-yee
    Chan, Eric Yat-tung
    Li, Handong
    Zhang, Xiuxia
    Chow, Pok-yu
    Liu, Po-ling
    Leung, Shuk-yu
    Chan, Chung-hong
    Chan, Ka-yan
    Chan, Johnny Yick-chun
    Ng, Jonathan Pak-heng
    Ng, Daniel Kwok-keung
    COMPLEMENTARY THERAPIES IN MEDICINE, 2016, 29 : 219 - 228
  • [43] BAMBUTEROL IN THE TREATMENT OF ASTHMA - A PLACEBO-CONTROLLED COMPARISON OF ONCE-DAILY MORNING VS EVENING ADMINISTRATION
    DALONZO, GE
    SMOLENSKY, MH
    FELDMAN, S
    GNOSSPELIUS, Y
    KARLSSON, K
    CHEST, 1995, 107 (02) : 406 - 412
  • [44] Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial
    Ashley Woodcock
    Eric D Bateman
    William W Busse
    Jan Lötvall
    Neil G Snowise
    Richard Forth
    Loretta Jacques
    Brett Haumann
    Eugene R Bleecker
    Respiratory Research, 12
  • [45] Acute Rejection Characteristics From a Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Early Corticosteroid Withdrawal
    Gaber, A. Osama
    Moore, Linda W.
    Alloway, Rita R.
    Woodle, E. Steve
    Pirsch, John
    Shihab, Fuad
    Henning, Alice
    Fitzsimmons, William
    Holman, John
    Reisfield, Robin
    First, M. Roy
    TRANSPLANTATION, 2013, 95 (04) : 573 - 579
  • [46] A phase 1 randomized, double-blind, placebo-controlled, crossover trial of DAS181 (Fludase®) in adult subjects with well-controlled asthma
    Colombo, Rhonda E.
    Fiorentino, Charles
    Dodd, Lori E.
    Hunsberger, Sally
    Haney, Carissa
    Barrett, Kevin
    Nabha, Linda
    Davey, Richard T., Jr.
    Olivier, Kenneth N.
    BMC INFECTIOUS DISEASES, 2016, 16
  • [47] A phase 1 randomized, double-blind, placebo-controlled, crossover trial of DAS181 (Fludase®) in adult subjects with well-controlled asthma
    Rhonda E. Colombo
    Charles Fiorentino
    Lori E. Dodd
    Sally Hunsberger
    Carissa Haney
    Kevin Barrett
    Linda Nabha
    Richard T. Davey Jr.
    Kenneth N. Olivier
    BMC Infectious Diseases, 16
  • [48] Double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of short-course low-dose oral prednisolone in pityriasis rosea
    Sonthalia, Sidharth
    Kumar, Akshy
    Zawar, Vijay
    Priya, Adity
    Yadav, Pravesh
    Srivastava, Sakshi
    Gupta, Atula
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 (06) : 617 - 622
  • [49] Efficacy and safety of 10 mg versus 30 mg of oral prednisolone for acute CPP crystal arthritis: findings of a randomized controlled trial
    Leelasattakul, Wuttirak
    Pongsittisak, Wanjak
    Manavathongchai, Siriporn
    Satpanich, Panchalee
    CLINICAL RHEUMATOLOGY, 2024, 43 (12) : 3879 - 3888
  • [50] Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial
    Straumann, A.
    Conus, S.
    Grzonka, P.
    Kita, H.
    Kephart, G.
    Bussmann, C.
    Beglinger, C.
    Smith, D. A.
    Patel, J.
    Byrne, M.
    Simon, H-U
    GUT, 2010, 59 (01) : 21 - 30